Myelofibrosis (MF) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top Key players Novartis, AbbVie, Nippon Shinyaku Co Ltd, Celgene, Sierra Oncology, Promedior, Inc., Samus Therapeuti

MF is an uncommon ailment described by the presence of excessive scar tissues in bone marrow that diminishes its hematopoietic potential. MF is the causes of a genetic mutation in the blood stem cells. However, the primary cause of this genetic mutation is clinically unidentified. Mutation in Janus Kinases 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL), calreticulin (CALR), and tet methylcytosine dioxygenase 2 (TET2) are expected to cause this disorder. Symptoms of MF include fever, bone pain, excessive sweating, shortness of breath, and weakness. The other problems related with MF are immense pain in bones and joints, leukemia, and hypertension. The disease can be analyzed by performing tests including blood test, physical examination, hereditary test, bone marrow examination, computed tomography (CT) scan, and magnetic resonance imaging (MRI) scans.

Download the sample report at: https://www.pharmaproff.com/request-sample/1227

Jakafi (Incyte Corporation) is the only drug approved by the U.S. Food and Drug Administration (USFDA) for the treatment of MF. The other treatment regimens include chemotherapy, radiation therapy, surgical removal of spleen, and stem cell therapy.
According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been found that the topical route of administration is easy to use and non-invasive, and ensures high level of patient’s satisfaction.

Get the detailed analysis at: https://www.pharmaproff.com/report/myelofibrosis-therapeutics-pipeline-analysis

Companies that are involved in developing therapeutics for MF have shown positive clinical results in various phases of drug development. For instance, in August 2016, CTI BioPharma Corp. announced positive data of phase III trial of pacritinib for the treatment of patients with MF. The results of the study concluded that treatment with pacritinib has a favorable safety and tolerability profile. The study also recorded efficacy of pacritinib with a 35% spleen volume reduction (SVR) from the baseline.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1227

An analysis done for pipeline products demonstrated that pacritinib, INC424, and Ruxolitinib are the leading product candidates for the treatment of MF. With the approval of these candidates and rising development of other pipeline products will cater the growth of the MF therapeutics market in the next 10 years.

Incyte Corporation, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Novartis International AG, AbbVie Inc., Nippon Shinyaku Co. Ltd., Celgene Corporation, Sierra Oncology Inc., Promedior Inc., Imago BioSciences, Samus Therapeutics Inc., Constellation Pharmaceuticals Inc., and Kartos Therapeutics Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of MF.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.